Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 30,258 |
|
|||||
| News | - | ||||||
| Day High | 20.15 | Low High |
|||||
| Day Low | 18.89 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CervoMed Inc | CRVO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.75 | -3.80% | 19.01 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 19.51 | 18.89 | 20.15 | 19.01 | 19.76 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,980 | 30,258 | $ 19.69 | $ 595,703 | - | 4.22 - 26.3789 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 381 | $ 19.01 | USD |
CervoMed Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 24.97M | 5.67M | - | 7.15M | -2.17M | -0.38 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
CervoMed News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRVO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 19.18 | 21.45 | 18.10 | 19.37 | 44,255 | -0.17 | -0.89% |
| 1 Month | 24.72 | 24.795 | 17.81 | 19.54 | 33,598 | -5.71 | -23.10% |
| 3 Months | 22.98 | 25.92 | 16.20 | 21.94 | 26,373 | -3.97 | -17.28% |
| 6 Months | 8.81 | 26.3789 | 5.85 | 17.85 | 26,149 | 10.20 | 115.78% |
| 1 Year | 13.50 | 26.3789 | 4.22 | 12.01 | 33,821 | 5.51 | 40.81% |
| 3 Years | 13.50 | 26.3789 | 4.22 | 12.01 | 33,821 | 5.51 | 40.81% |
| 5 Years | 13.50 | 26.3789 | 4.22 | 12.01 | 33,821 | 5.51 | 40.81% |
CervoMed Description
| Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. |
